CD47 functions as a “do not eat me” signal, binding to its receptor signal‐regulatory protein alpha (SIRP α) on macrophages and microglia, impeding their phagocytic capacity.[8] PD‐L1 interacts with PD‐1 expressed in T cells, blocking the activation of antigen‐specific effector T cells.[9] Since 2010, multiple monoclonal antibodies targeting different ICPs (e.g., PD‐1, PD‐L1, CTLA‐4, CD47) have been developed[10] and are now integrated into the standard of care for treating melanoma, non‐small cell lung cancer, and other solid tumors.[11, 12]. Here, CD47 is linked to melanoma.